News

NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders. Ennio Ongini, vice president

Twelve subjects will be randomly assigned to one of two groups of R(+) isomer zileuton (100mg or 300mg). The trial is designed to confirm that the R(+) isomer

This grant will support further scientific development of NOV-002, in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track. Christopher

The study will evaluate three different doses of PYY3-36 nasal spray compared to placebo and sibutramine (Meridia), a commercially available oral weight loss drug. Patients in the active

Under the agreement, PerkinElmer will commence a cash tender offer to purchase all of the outstanding shares of ViaCell for $7.25 per share, for an aggregate purchase price

The companies intend to deploy these systems in support of drug discovery and clinical programs. Under the terms of the agreement, OSI will pay Aveo a total upfront

Mylan says it will benefit from substantial operational efficiencies and economies of scale from increased sales volumes and its vertically and horizontally integrated platform. The deal makes Mylan

Enjuvia is claimed to be the first and only plant-derived oral estrogen approved by FDA for the treatment of these specific symptoms associated with vaginal atrophy. James Simon,

The biologics license application (BLA) submission is based on data from the company’s pivotal Phase III acute trial which met its protocol-defined, pre-specified primary endpoint with statistical significance